JPRN-UMIN000010386招募中2 期
Randomized phase II study with or without adjuvant immunotherapy of alpha-GalCer-pulsed dendritic cells in the patients with completely resected stage II-IIIA non-small cell lung cancer - Randomized phase II of adjuvant immunotherapy using alpha-GalCer-pulsed dendritic cells in completely resected stage II-IIIA non-small cell lung cancer (RADCLC)
ational Hospital Organization Kyushu Cancer Center0 个研究点目标入组 60 人开始时间: 2013年4月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Serious concomitant disease including severe infectious disease or malnutrition. 2) Postoperative pleural effusion or ascites or cardiac effusion which need to be controlled. 3) The patient who have simultaneous malignancy or who have metachronous malignancy within 5 years-disease free interval. 4) Concurrent corticosteroid therapy 5)Autoimmune disease 6) History of hepatitis 7) Positive response to HIV, hepatitis C virus or human T cell lymphotrophic virus antibodies or those with HBs antigen. 8) Severe cardiac disease(NYHA class III or IV) or severe pulmonary disease (greater than Hugh-Jones Classification III) 9) History of hyper-reactivity to albmin 10) Pregnancy or lactation 11) Contraindication to apheresis (angina, greater than atrioventricular block 2 degree, WPW syndrome, complete left bundle branch block, systolic blood pressure with 90 Torr or greater than 170 Torr) 12) The patients have been judged to be inappropriate to participate in this study by principal investigator.
研究者
相似试验
进行中（未招募）
1 期
A Randomized Phase-2 Trial to Evaluate the Effects of the IRX-2 Regimen before Surgery and after Chemotherapy or Radiation in Newly Diagnosed Patients with Stage II, III or IVA Squamous Cell Cancer of the Oral Cavityewly Diagnosed Stage II, III or IVA Squamous Cell Carcinoma of the Oral Cavity.MedDRA version: 19.0Level: PTClassification code 10041857Term: Squamous cell carcinoma of the oral cavitySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-000373-21-ESIRX Therapeutics, Inc.200
进行中（未招募）
1 期
A Randomized Phase-2 Trial to Evaluate the Effects of the IRX-2 Regimen before Surgery and after Chemotherapy or Radiation in Newly Diagnosed Patients with Stage II, III or IVA Squamous Cell Cancer of the Oral Cavityewly Diagnosed Stage II, III or IVA Squamous Cell Carcinoma of the Oral Cavity.MedDRA version: 20.0Level: PTClassification code 10041857Term: Squamous cell carcinoma of the oral cavitySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-000373-21-HUIRX Therapeutics, Inc.200
进行中（未招募）
1 期
A Randomized Phase-2 Trial to Evaluate the Effects of the IRX-2 Regimen before Surgery and after Chemotherapy or Radiation in Newly Diagnosed Patients with Stage II, III or IVA Squamous Cell Cancer of the Oral Cavityewly Diagnosed Stage II, III or IVA Squamous Cell Carcinoma of theOral Cavity.MedDRA version: 20.0Level: PTClassification code 10041857Term: Squamous cell carcinoma of the oral cavitySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-000373-21-ITIRX THERAPEUTICS, INC.200
进行中（未招募）
1 期
Study in kidney cancer patients with at least the kidney tumor present and sometimes enlarged lymph nodes in the vicinity of the affected kidney, in which the subjects first receive an immunotherapy treatment, which may consist of either nivolumab alone, or the combination of nivolumab and ipilimumab, or the combination of nivolumab and relatlimab, after which the kidney tumor (and possibly enlarged lymph nodes) is removed.primary clear cell renal cell cancer at risk for recurrence or distant metastasesMedDRA version: 20.0Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: HLGTClassification code 10038364Term: Renal and urinary tract neoplasms malignant and unspecifiedSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2021-002360-51-NLAntoni van Leeuwenhoek ziekenhuis69
招募中
2 期
Prospective, randomized, neoadjuvant phase II study with combination immuno-oncology in primary clear cell renal cell cancer at risk for recurrence or distant metastases (NESCIO-trial; M21NSC; CA209-6DJ)kidney cancer10038364clear cell renal cell carcinomaNL-OMON52016Antoni van Leeuwenhoek Ziekenhuis46